Kornimate/medical-research-clean huggingface dataset:
family promoting positive emotions pilot study

Conditions: Depression; Anhedonia; Stress; Depressive Disorder; Behavioral Symptoms; Mood Disorders; Mental Disorder; Mood Disturbance

Summary: anhedonia is characterized by loss of interest or pleasure. the proposed pilot study would be the first to test an innovative, neuroscience-informed intervention in mothers reporting depressive symptoms and stress to enhance positive emotionality with the goal of preventing anhedonia and associated emotional disturbances in their children. this study will recruit dyads (mothers and their children) for the intervention.

anhedonia, characterized by loss of interest or pleasure, is a primary symptom of depression. depression is increasingly prevalent and can cause significant impairments in life functioning. given the increased presence of stress during covid-19, there is a significant need for interventions that can prevent the development of anhedonia and depression. this study examines a neuroscience-informed positive emotion intervention to determine its effects on preventing anhedonia and associated emotional disturbances in dyads of children and their mothers. participants will be randomized to either receive the positive emotion intervention for 8 sessions for 8 weeks with a clinician or the self-administered written information condition. depressive symptoms, anhedonia, stress and other internalizing disorders will be assessed at baseline, and at the end of the intervention.

Eligibility criteria:
inclusion criteria for mothers: * age 18 and older who report at least subthreshold current depressive symptoms (\> score of 8 on the patient health questionnaire) and moderate covid-19-related stress * can read and speak in english. * have access to a computer with a videoconferencing platform. inclusion criteria for children: * age 8-12 years who can participate with their biological mother who is 18 years or older that meets the above criteria. * can read and speak in english. exclusion criteria for mothers: * current substance use disorder. * intellectual disabilities. * diagnosis of mania or bipolar disorder. * diagnosis of a psychotic disorder (e.g., schizophrenia). * visual or hearing impairments that interfere with completing study measures and sessions. exclusion criteria for children: * diagnoses of autism spectrum disorders or developmental disorders. * intellectual disabilities. * diagnosis of mania or bipolar disorder. * diagnosis of a psychotic disorder (e.g., schizophrenia). * currently experiencing depressive symptoms. * visual or hearing impairments that interfere with completing study measures and sessions. * offspring of mothers who have previously participated in the study with another biological child.

Keywords: depression anhedonia stress reward mental disorders mood disorders
attempted suicide short intervention program for older adults (assip-oa): an evaluation of a psychosocial intervention for suicidal adults aged 65+

Conditions: Suicidal Ideation; Suicide Attempt; Suicide

Summary: older adults are sorely underrepresented in suicide prevention research, despite the fact that suicide rates are higher in this age group than in any other age group in sweden and in many countries worldwide. there are extremely few clinical intervention studies that target this age group, with to date no published studies in europe. the overall aim is to develop and test a modified version of the attempted suicide short intervention program (assip), which the investigators will adapt specifically for older adults (65+). the original assip was developed in switzerland where it has shown an 80% decrease in risk of new suicide attempts compared to ordinary treatment. in sweden, assip is currently being tested for persons aged 18+ . the investigators now propose a randomised controlled trial (rct) to evaluate a modification of assip specifically designed to meet the needs of suicidal persons aged 65 and above, the assip-older adult program (assip-oa). main study questions 1. compared to treatment as usual (tau), will the addition of the assip-oa to ordinary treatment have a preventive effect on suicide and suicide attempts within 6, 12, and 24 months following the index episode? 2. compared to tau, do assip-oa participants show better improvement in coping skills and psychiatric symptoms a) after the last session and b) at 6-,12- and 24- month follow-up? 3. is a brief preventive intervention (assip-oa) for older adults feasible, based on its acceptability, appropriateness, deliverability and fidelity? do participants experience side effects? do they have fewer days of inpatient care? 4. what kind of challenges and opportunities do a) older adults and b) assip-oa therapists experience in relation to implementing a brief preventive intervention like assip-oa? are the modifications that the investigators made in assip-oa relevant for older adults?


Eligibility criteria:
inclusion criteria: 1. age 65 and above at time of index suicide attempt or hospitalisation for serious suicidal plans. 2. a mental health care contact during the active treatment period. 3. capable of understanding study procedures and providing informed consent. exclusion criteria: 1. clinical diagnosis of dementia or moca score less than -2 standard deviations from the normative score for education and age (borland et al., 2017). ongoing delirium, or any other condition impeding the comprehension of the study's procedures and implications that hinder the provision of informed consent. 2. severe ongoing psychosis, severe ongoing substance use disorder, emotionally instable personality syndrome and any other condition that would require longer specialized treatment to reduce future suicidal behaviour (e.g. dbt). 3. terminal illness. 4. insufficient knowledge of the swedish language (requires interpreter). 5. aphasia or other severe communication issue or severe hearing and/or severe visual impairment that render the intervention unfeasible despite corrective aids.
minimally invasive surgery in crohn's disease: laparoscopic vs robotic

Conditions: Crohn Disease; Surgery

Summary: retrospective observational cohort study including patients with crohn's disease undergoing minimally invasive ileocolic resection.

all consecutive patients with crohn's disease (cd) who underwent minimally invasive ileocolic resection from 2014 at mayo clinic were retrospectively identified using a prospectively maintained institutional database.

Eligibility criteria:
inclusion criteria: * crohn's disease * ileocolic resection exclusion criteria: - n/a

Keywords: crohn disease minimally invasive surgery ileocolic resection outcomes complication enhanced recovery after surgery
therapeutic massage for generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: the purpose of this study is to compare the relative effectiveness of three relaxation treatments (therapeutic massage, thermotherapy, and time in a relaxing environment) in reducing anxiety in persons with generalized anxiety disorder.

anxiety and stress are costly problems that afflict millions of american adults. together, they are among the most common reasons for which adults use complementary and alternative medical (cam) therapies as well as more conventional relaxation therapies. although massage is one of the most popular cam treatments for anxiety, its effectiveness for this problem has never been rigorously evaluated. this study is designed to evaluate the effectiveness of massage as a treatment for a diagnosed anxiety disorder. massage will be compared with two other relaxing treatments: thermotherapy and time in a relaxing environment, which reflect the types of activities that persons with anxiety might try to relieve their symptoms.

Eligibility criteria:
inclusion criteria: * member of group health, seattle metropolitan area * generalized anxiety disorder confirmed by scid * at least moderate anxiety exclusion criteria: * serious mental health co-morbidity * any life threatening condition * currently receiving psychotherapy * substantial alcohol use * contraindications for massage

Keywords: massage therapy relaxation treatments
silver diamine fluoride in molar-incisor hypomineralisation

Conditions: Molar-Incisor Hypomineralisation

Summary: the objective of this study is to assess the efficacy of silver diamine fluoride application in molars affected by molar-incisor hypomineralization. additionally, the study aims to evaluate the effectiveness of the combined application of silver diamine fluoride, commonly used for dentin hypersensitivity, with a glass hybrid restorative system. the goal is to mitigate sensitivity and improve chewing functions in teeth affected by molar-incisor hypomineralization.

in a research study focusing on 120 children aged 8-13 with molar incisor hypomineralization (mih), a comprehensive examination of 240 teeth will be conducted. study will employ selective caries removal to eliminate decay and subsequently apply restorations. the two intervention groups are delineated as follows: group 1: glass hybrid restorative system (equia forte, gc europe, leuven, belgium) group 2 : restoration involving fluoride varnish (sdi riva star) + glass hybrid restorative system (equia forte, gc europe, leuven, belgium)

Eligibility criteria:
inclusion criteria: * children aged between 8 and 13 who are cooperative, having at least 2 teeth with a bakh-tii score of 4a or 4b. * complete occlusion of teeth with mih. * presence of signs of pulpal pathology with symptoms in the teeth included in the study during the pre-treatment clinical examination (absence of spontaneous and prolonged pain, no percussion and palpation sensitivity, no swelling or fistula in soft tissue, presence of periapical radiolucency in radiographs, and absence of internal or external resorption). * additionally, no parafunctional habits (e.g., bruxism) and no malocclusion (posterior crossbite). * good general health condition, without systemic illnesses. * absence of silver allergy. exclusion criteria: * non-cooperative individuals. * having mih severity outside the specified scoring. * presence of systemic diseases. * lack of complete occlusion in the molars. * presence of parafunctional habits. * presence of pulpal pathology. * individuals with a silver allergy.
efficacy and safety of the acat inhibitor cs-505 (pactimibe) for reducing the progression of coronary artery disease

Conditions: Coronary Heart Disease

Summary: the purpose of this study is to learn if cs-505 is safe and effective for slowing down or possibly reversing the buildup of tissue, cells and fatty deposits (plaque) in the blood vessels of the heart (coronary artery atherosclerosis).


Eligibility criteria:
inclusion criteria: standard: 1. male or female subjects, age 18 years or greater; and 2. diagnosed or suspected coronary artery disease with a clinical indication for coronary angiography. angiographic: 1. evidence of coronary heart disease 2. identification of a target native coronary artery for the plaque volume measurement. exclusion criteria: standard: 1. breast feeding or lactating women, or women who have had a pregnancy (regardless of outcome) within the past 12 months; 2. previous heart or other organ transplantation; 3. treatment with any of the following agents within 4 weeks prior to randomization: * immunosuppressive agents (cyclosporine, azathioprine); * rifampin; and * phenytoin, phenobarbital, valproic acid, or other anticonvulsants. 4. any of the following manifestations of cardiac disease: * myocardial infarction or unstable angina within 24 hours prior to randomization or clinically unstable; * clinically significant heart disease; and * coronary artery bypass surgery within previous 3 months. 5. stroke (cva) within previous 3 months; 6. evidence of severe symptomatic heart failure (nyha class iii or iv) or known ejection fraction less than 30%; 7. uncontrolled diabetes mellitus; 8. uncontrolled hypertension; and 9. nephrotic syndrome, significant nephropathy, or other significant renal disease. angiographic: 1. presence of any lesion with greater than 50% reduction in lumen diameter; or 2. any lesion with a greater than 50% occlusion in the left main coronary artery; 3. a target vessel, including any of its branches, that has undergone or will be undergoing coronary artery bypass grafting (cabg) or percutaneous coronary intervention (pci); 4. a target vessel that is itself a bypass graft.

Keywords: atherosclerosis, intravascular ultrasound
sweetheart-register: risk management of diabetics with acute myocardial infarction

Conditions: Diabetes; STEMI; NSTEMI; Myocardial Infarction

Summary: the sweetheart register (risk management of diabetics with acute myocardial infarction) documents both the prevalence of pathologic glucose metabolism in consecutive high-risk patients with stemi and nstemi in daily hospital routine as well as the anti-diabetic acute and long-term therapy. furthermore the register will provide data about the implementation of new guidelines for the interventional and adjuvant medical therapy of stemi and nstemi.


Eligibility criteria:
inclusion criteria: * consecutive patients with acute (no older than 24 h) st-elevation myocardial infarction * consecutive patients with acute (no older than 24 h) non-st-elevation myocardial infarction exclusion criteria: * missing informed consent

Keywords: diabetes stemi nstemi myocardial infarction
two stage study of combination of chemotherapy, shr-1210 and/or decitabine for relapsed/refractory pmbcls

Conditions: Primary Mediastinal Large B-cell Lymphoma

Summary: this is a two stage, phase i/ii clinical trial for patients with relapsed or refractory primary mediastinal large b-cell lymphoma (rrpmbcl). in the first stage, the participants will receive gvd (gemcitabine, vinorelbine and doxorubicine) chemotherapy and pd-1 antibody (shr-1210) treatment. the safety and efficacy of combined regimen will be evaluated. if deemed safe and efficacious, the investigators will proceed to the second stage of the study. in the second stage, the participants will receive gvd chemotherapy and shr-1210 treatment with low-dose decitabine priming. the safety and feasibility of combined regimens will be evaluated in phase i study. the feasibility will be accessed.


Eligibility criteria:
inclusion criteria: 1. all patients had histologically proven pmbcl, and radiographically measureable disease. 2. eastern cooperative oncology group performance status 0-2 3. disease recurring within 6 months after first-line chemotherapy or disease progression while receiving or persistent disease after first-line chemotherapy 4. bulky disease was defined as the presence of a mediastinal mass \> 4.5 cm in axial diameter or extranodal lesion \> 3 cm. 5. subjects must have received at least two prior chemotherapy regimen, and must be off therapy for at least 4 weeks prior to day 1. subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months. subjects with anti-pd-1 antibody are eligible which must be resistance. 6. adequate organ function. 7. female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug. 8. male participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through 120 days after the last dose of study drug. exclusion criteria: 1. known clinically active central nervous system involvement. 2. any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications. 3. serious uncontrolled medical disorders or active infections, pulmonary infection especially 4. prior organ allograft. 5. receiving any other form of immunosuppressive medication, except steroid. 6. allogeneic hematopoietic stem cell transplantation within the last 5 years. 6） known human immunodeficiency virus (hiv). 7） has received a live vaccine within 30 days prior to first dose of study drug. 8） women who are pregnant or breastfeeding.

Keywords: relapsed/refractory primary mediastinal large b-cell lymphoma pd-1 antibody decitabine gvd chemotherapy
influence of menstrual cycle phases on the glycemic control of aerobic or hiit exercise in adult women with type 1 diabetes

Conditions: Diabetes Mellitus, Type I; Menstruation

Summary: continuous glucose monitors, as a technology that aims to improve glycaemic control in patients with type 1 diabetes, must always adjust to changes in blood glucose levels in these patients, e.g. during sporting activities. in women, in particular, menstruation and its different phases can affect blood glucose levels in different ways. therefore, this study aims to determine whether there is a different behaviour of blood glucose levels during aerobic or high-intensity exercise in different phases of menstruation. if so, we will try to model this behaviour and create specific guidelines in this regard in terms of physical exercise programming in women. in addition, the information derived from this study will be used to design better artificial pancreas systems that take into account the effects of the menstrual cycle in women.


Eligibility criteria:
inclusion criteria: age between 18-45 years t1d with a diabetes duration for more than 2 years glycated hemoglobin (hba1c) \< 8.5% (\<69 mmol mol-1) stable insulin regimen in the past 6 months with less than 20% change in total insulin daily dose multiple daily injections or insulin pump weekly physical activity of 90 min or more, but no practicing any sport as amateur or professional. exclusion criteria: clinical conditions or use of medications (other than insulin) known to affect glycemic control (e.g., oral/parenteral steroids or metformin, among others).
maintenance therapy after thalidomide-dexamethasone(thadd) for multiple myeloma(mm)

Conditions: Multiple Myeloma

Summary: this is randomized, multicentre study aimed to compare a standard maintenance therapy with interferon-dexamethasone with an experimental therapy based on thalidomide-dexamethasone in patients with multiple myeloma who responded to thadd induction therapy

thalidomide has already been used as maintenance and/or consolidation after high-dose therapy followed by autologous stem cell transplantation. despite a number of phase ii and iii studies the issues of right dose and duration of thalidomide and subsets of patients benefiting from it have not yet been settled we explored the maintenance therapy after thalidomide, dexamethasone and pegylated liposomal doxorubicin called thadd protocol. patients with de novo or relapsed mm obtaining at least minor response after 4 to 6 thadd courses, were randomized to receive standard maintenance therapy with ifn 3 mu 3 times a week or an experimental maintenance therapy such as thalidomide 100 mg per day until relapse or intolerable side effects. both groups also received pulsed dexamethasone 20 mg 4 days a month.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed or advanced multiple myeloma achieving at least a minimal response after induction with thadd regimen * written consent exclusion criteria: * peripheral neuropathy \>= grade 2 * neutropenia \< 1000/mcl or thrombocytopenia \< 50000/mcl * severe depression * organ disfunction \> grade 2

Keywords: thalidomide maintenance interferon dexamethasone newly diagnosed multiple myeloma relapsed refractory multiple myeloma
the effect of administration of low dose adrenaline during surgery on bleeding during hip surgery

Conditions: Intraoperative Blood Loss

Summary: the purpose of this study is to evaluate the effect of intraoperative administration of low-dose adrenaline on intraoperative blood loss in patients undergoing hip surgery.

hip arthroplasty is associated with bleeding, anemia and the need for allogeneic transfusion. administration of low-dose adrenaline activates the coagulation system and may decrease intraoperative and immediate postoperative bleeding. thus, the aim of this study is to evaluation whether intraoperative iv-administration of low-dose adrenaline reduces bleeding in elective total hip arthroplasty.

Eligibility criteria:
inclusion criteria: * age \> 18 years. * scheduled for primary unilateral hip arthroplasty * able to give consent exclusion criteria: * allergy towards adrenaline * current treatment with: adp receptor inhibitors or vitamin k antagonists (within 5 days), factor xa inhibitors or thrombin inhibitors (within 1 day), heparin (excluding low molecular weight heparin for perioperative thromboprophylaxis). * current treatment with tricyclic antidepressants * use of mao inhibitors (within previous 14 days) or comt inhibitors (within 2 days). * acute coronary syndrome / myocardial infarction within the previous 6 months. * not willing to accept blood transfusion * participation in other clinical trial within previous 30 days * women of childbearing age (without menopause for at least 12 months) * glaucoma * pheochromocytoma * low serum k+ (\< 3.0 mmol/l) * thyrotoxicosis * digoxin intoxication * alcohol og drug abuse (investigators judgement)
emergency department ultrasound in renal colic

Conditions: Renal Colic; Hydronephrosis; Abdominal Aortic Aneurysm

Summary: renal colic is a common (1300 visits per year at our institution) and painful condition caused by stones in the kidney and ureter, and can be mimicked by life threatening conditions such as a ruptured abdominal aortic aneurysm (aaa). this can create clinical uncertainty. emergency department targeted ultrasound (edtu) is performed by an emergency physician at the patient's bedside, and has been shown to be accurate, safe, and efficient. we have shown that edtu can accurately identify hydronephrosis, which is a predictor of complications of kidney stones. a normal formal ultrasound (us) predicts an uncomplicated clinical course. we will assess the accuracy of edtu for the diagnosis of hydronephrosis, and when normal, whether patients can be safely discharged.


Eligibility criteria:
inclusion criteria: * age 16 - 65 years * symptoms suggestive of renal colic * edtu performed within one hour (before or after) of formal imaging * imaging study arranged during this ed visit (includes next morning) exclusion criteria: * hemodynamic instability (pulse \> 120 or sbp \< 90 or requiring vasopressors) * fever (\>38 degrees c) * leukocytes and nitrites on dipstick urinalysis (evidence of urinary tract infection) * pregnancy * inmate * renal transplant or single functioning kidney

Keywords: renal colic hydronephrosis abdominal aortic aneurysm ultrasound emergency medicine urolithiasis
chocolate balloon angioplasty registry

Conditions: Peripheral Arterial Disease

Summary: to collect data from real-world use with the chocolate pta balloon catheter to support the effectiveness of the device for use during percutaneous transluminal angioplasty (pta) procedures.


Eligibility criteria:
inclusion criteria: 1. \>18 years of age 2. lesion successfully crossed with a guide-wire 3. reference vessel diameter (rvd) within the treatment range of the chocolate pta catheter used at the target lesion appropriate for 1:1 dilatation 4. patient has given consent for their information to be submitted to this registry exclusion criteria: 1. lesion required stenting as the primary treatment approach 2. life expectancy \<12 months 3. patient is enrolled in another clinical study that may impact the results of this registry